Abstract 910
Background
Liver cancer is the fifth commonest cancer. As per the World Health Organization liver disease is the tenth most common cause of death in India. Among all liver cancers, Hepatocellular carcinoma (HCC) is the most frequent cause and comprises 90% of liver cancer. Liver cancer is one of the leading causes of death worldwide due to its aggressive nature and poor survival rate. Due to the advancement of new technologies, the demand of high quality of biological samples has increased for translational research and drug discovery. Biobank are a suitable place to get a high quality of annotated biosamples. Biobank are playing important role in the field of cancer research, diagnosis, prognosis, and treatment. Most of the Biobank are situated in economically developed countries while cancer and other related disease are more in developing countries. The Indian government has established a world-class National Liver Disease Biobank in 2017 with a capacity of 5.4 million samples. Its aim is to accelerate research and personalized treatment in India.
Methods
The Biobank has collaboration with different hospitals from all over India. It is following Decentralized collection, centralized storage, and informatics. All centers are collecting biosamples as per SOPs of National Liver Disease Biobank.
Results
The Biobank collects, process and store a wide array of biospecimens (tumor tissue, adjacent normal tissue, blood, plasma, serum, buffycoat……) using validated SOPs. At present Our Biobank has collaboration with three hospitals and four research centers. It has collected 2566 biosamples and has involved in many research projects.
Conclusions
Establishment of the biobank is a major step in liver cancer related clinical and basic research in India The aim of NLDB Biobank is to accelerate HCV, liver disease, and associated cancer research. It is a first and biggest Liver Biobank in India, have a network from different hospitals across the country. We have been involving in many research projects which results would be highly useful in patient care and cancer research, biomarker discovery and translational research.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
National Liver Disease Biobank.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
780 - The adipocyte suppresses the inhibitory role of hsa_circ_0000190 in the metastasis of breast cancer cells
Presenter: Xiu Chen
Session: Poster display - Cocktail
Resources:
Abstract
782 - CircASS1 suppressed the invasion and metastasis ability of breast cancer cell line by targeting gene ASS1 and harboring miR-4443
Presenter: Junchen Hou
Session: Poster display - Cocktail
Resources:
Abstract
916 - Ex-vivo drug sensitivity of primary breast cancer stems cell populations to potentiate therapeutic strategy for treatment resistant breast cancer
Presenter: Sourav Nandi
Session: Poster display - Cocktail
Resources:
Abstract
928 - Molecular Tumor Board (MTB): development of clinical pathways for precision medicine. Experiences of Center for Breast cancer at National cancer center, Korea
Presenter: In Hae Park
Session: Poster display - Cocktail
Resources:
Abstract
1274 - MicroRNA based immune response signature identifies poor prognostic subgroup within ER negative breast cancers
Presenter: Savitha Rajarajan
Session: Poster display - Cocktail
Resources:
Abstract
165 - The clinical efficacy of apatinib combined with Xeloda in advanced triple negative breast cancer
Presenter: YiHui Li
Session: Poster display - Cocktail
Resources:
Abstract
561 - Quality of life and psychosocial needs of metastatic breast cancer patients
Presenter: Tahir Mehmood
Session: Poster display - Cocktail
Resources:
Abstract
697 - TC-1 mediate the TBC1D3 oncogene induced migration of MCF-7 breast cancer cells
Presenter: Yong Shen
Session: Poster display - Cocktail
Resources:
Abstract
784 - RelB facilitates cell migration and invasion in breast cancer via MMP1 upregulation
Presenter: Mei Wang
Session: Poster display - Cocktail
Resources:
Abstract
921 - Re-challenging eribulin in patients with ER+HER2- metastatic breast cancer: A single-institution experience
Presenter: Junichiro Watanabe
Session: Poster display - Cocktail
Resources:
Abstract